Dittrich, Christian
Königsberg, Robert
Mittlböck, Martina
Geissler, Klaus
Sahmanovic-Hrgovcic, Azra
Pleiner-Duxneuner, Johannes
Czejka, Martin
Buchner, Philipp
Funding for this research was provided by:
Österreichische Forschungsförderungsgesellschaft (811590)
Article History
Received: 11 March 2018
Accepted: 6 July 2018
First Online: 12 July 2018
Compliance with ethical standards
:
: CD’s non-profit research institutes (Ludwig Boltzmann-Institute for Applied Cancer Research (LBI-ACR VIEnna) and Applied Cancer Research – Institution for Translational Research Vienna, both forming the Central European Anticancer Drug Development Platform (CEADDP)) were funded by the Austrian Research Promotion Agency (FFG) – SELP (Strategisches Exzellenz Leitprojekt) Structural Programme, and the LBI-ACR VIEnna additionally by Roche Austria. CD received compensation as a member of a scientific advisory board of Roche Austria. He also consulted for Roche Austria and received compensation.MM has received compensation for statistical analyses of the study from Roche Austria.KG has received compensation as a member of scientific advisory boards and for presentations from Roche Austria.JP-D is Roche Austria employee.RK, AS-H, MC, and PB declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. The study protocol was approved by the Ethics Committee of the City of Vienna (reference number EK 08-159-0908).
: Informed consent was obtained from all individual participants included in the study.